OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam ‘enhancer’
Journal of Antimicrobial Chemotherapy2015Vol. 70(10), pp. 2779–2786
Citations Over TimeTop 10% of 2015 papers
Akihiro Morinaka, Yuko Tsutsumi, Mototsugu Yamada, Kenji Suzuki, Takashi Watanabe, Takao Abé, Takeshi Furuuchi, Seiichi Inamura, Yoshiaki Sakamaki, Nakako Mitsuhashi, Takashi Ida, David M. Livermore
Abstract
OP0595 acts in three ways: (i) as an inhibitor of class A and C β-lactamases, covalently binding at their active sites; (ii) as an antibacterial, by inhibiting PBP2 of several Enterobacteriaceae; and (iii) as an 'enhancer' of β-lactam agents that bind to other PBPs besides PBP2 for several Enterobacteriaceae. OP0595 has considerable potential to overcome resistance when it is combined with various β-lactam agents.
Related Papers
- → Recombinant Protein Expression in Escherichia coli (E.coli): What We Need to Know(2018)115 cited
- [A study on beta-lactamase activity of biofilm Escherichia coli].(2001)
- Bacteriostatic Experiment of Twelve Species of Chinese Medicines and Its Compounds Against Escherichia Coli(2004)
- Damaging effect of pressurized CO_2 on cell membrane of Escherichia coli(2013)
- A study on β-lactamase activity of biofilm Escherichia coli(2001)